quarta-feira, 7 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 25, 2026

T-Mobile Turns up the Value With the Samsung Galaxy S26 Lineup

View original at finance.yahoo.com
T-Mobile Turns up the Value With the Samsung Galaxy S26 Lineup Samsung’s newest Galaxy devices land at T-Mobile — with on Us offers, benefits worth switching for and a five-year price guarantee Get 5G Home Internet delivered same-day and bundle with a new Galaxy S26 for even more savings BELLEVUE, Wash., February 25, 2…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • T-Mobile's 5G Advanced network unlocks the full performance of the Galaxy S26, turning features like multi-carrier aggregation and uplink enhancements into noticeable real-world improvements in speed, responsiveness and reliability

    80% confidence

  • SuperMobile is the best business plan on the best network

    80% confidence

  • Combined with built-in benefits and a 5-year price guarantee on best plans, T-Mobile offers unmatched performance and value not found anywhere else

    80% confidence

  • This is T-Mobile's richest Galaxy offer ever and the first time T-Mobile customers can get the Galaxy S26 Ultra on Us

    80% confidence

  • T-Mobile's 5G network provides quicker uploads and downloads for large files and smooth 4K streaming even in crowded places like airports and events

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
T-Mobile Turns up the Value With the Samsung Galaxy S26 Lineup — Source | Via News | pt.VIA.NEWS